Department of Clinical Medicine, The Second School of Clinical Medicine, Anhui Medical University, Hefei, Anhui, China.
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.
Curr Pharm Des. 2023;29(6):468-473. doi: 10.2174/1381612829666230224092657.
Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephritis, which is mainly characterized by excessive IgA deposition in the glomerular mesangial area. Although exploring the pathogenesis of IgAN and improving the treatment strategies continuously, the exact pathogenesis of IgAN remains unclear and the disease still leads to high mortality. Recently, emerging evidence has demonstrated that dysregulated intestinal mucosal immunity and gut microbiome imbalance may play a combined role in the development and progression of IgAN. It has been suggested that reconstructing the intestinal microenvironment and maintaining the stability and metabolic balance of gut microbiome are expected to become new treatment strategies. Meanwhile, inhibiting mucosa-associated lymphoid tissue (MALT) controlled by the gut microbiome may become an alternative treatment, especially used to reduce the excessive production of IgA in IgAN. In this review, we summarized the correlation between gut microbiome and the pathogenesis of IgAN, as well as the therapeutic potential of gut microbiome in this disease.
免疫球蛋白 A 肾病（IgAN）是一种常见的原发性肾小球肾炎，主要特征是 IgA 在肾小球系膜区过度沉积。尽管不断探索 IgAN 的发病机制并改进治疗策略，但 IgAN 的确切发病机制仍不清楚，该病仍导致高死亡率。最近，新出现的证据表明，失调的肠道黏膜免疫和肠道微生物组失衡可能在 IgAN 的发生和发展中起共同作用。有人提出，重建肠道微环境和维持肠道微生物组的稳定性和代谢平衡有望成为新的治疗策略。同时，抑制受肠道微生物组控制的黏膜相关淋巴组织（MALT）可能成为一种替代治疗方法，特别是用于减少 IgAN 中 IgA 的过度产生。在这篇综述中，我们总结了肠道微生物组与 IgAN 发病机制的相关性，以及肠道微生物组在该疾病中的治疗潜力。
